Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to metastatic disease sites, reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, compared to a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million versus $2.2 million last year, while G&A expenses were $3.1 million compared to $3.6 million. Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash. Recent highlights include new preclinical data on CLD-401 from the proprietary RedTail platform, showing enhanced efficacy through systemic delivery of an IL15 superagonist and immune-evasion via engineered CD55 expression; $4.6 million raised in a warrant inducement offering, bringing 2025 gross proceeds to $15.7 million; and FDA Fast Track Designation for CLD-201 in soft tissue sarcoma, with an open IND for a Phase 1 trial.
To view the full press release, visit: https://ibn.fm/K3CfE
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
